Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Simufilam - Cassava Sciences

Next Previous
Drug Profile

Simufilam - Cassava Sciences

Alternative Names: C0105; C0105M; Filora; PTI-125; PTI-910; Simufilam hydrochloride; Sumifilam - Cassava Sciences

Latest Information Update: 12 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pain Therapeutics
  • Developer Cassava Sciences
  • Class Antidementias; Small molecules
  • Mechanism of Action Microfilament protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 07 Feb 2024 Topline adverse events and efficacy data from the phase II trial in Alzheimer's disease released by Cassava Sciences
  • 08 Jan 2024 Cassava Sciences plans a phase I pharmacokinetics trial for Alzheimer's disease (In volunteers) in February 2024 (PO) (NCT06195319)
  • 10 Nov 2023 Cassava Sciences completes enrolment in the phase III clinical trial in Alzheimer's disease in USA, Canada, South Korea, and Puerto Rico (PO) (NCT05026177)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top